Celcuity (NASDAQ:CELC) Hits New 52-Week High – Time to Buy?

Celcuity, Inc. (NASDAQ:CELC) shares hit a new 52-week high during mid-day trading on Monday . The company traded as high as $102.15 and last traded at $101.8880, with a volume of 248158 shares traded. The stock had previously closed at $97.50.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Guggenheim began coverage on Celcuity in a research report on Monday, September 22nd. They set a “buy” rating for the company. Stifel Nicolaus boosted their price objective on shares of Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Craig Hallum upped their target price on shares of Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Wolfe Research initiated coverage on shares of Celcuity in a research report on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price target on the stock. Finally, HC Wainwright reissued a “neutral” rating and issued a $94.00 price target (up previously from $77.00) on shares of Celcuity in a report on Monday, November 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

Celcuity Stock Up 1.3%

The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26. The firm’s fifty day simple moving average is $67.01 and its 200 day simple moving average is $41.33. The stock has a market capitalization of $4.64 billion, a price-to-earnings ratio of -27.34 and a beta of 0.72.

Celcuity (NASDAQ:CELC) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.13. On average, sell-side analysts forecast that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Insiders Place Their Bets

In other Celcuity news, Director Richard E. Buller sold 3,900 shares of the stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $96.73, for a total transaction of $377,247.00. Following the completion of the transaction, the director owned 7,260 shares in the company, valued at approximately $702,259.80. This represents a 34.95% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 15.78% of the company’s stock.

Institutional Trading of Celcuity

Institutional investors have recently modified their holdings of the company. Baker BROS. Advisors LP grew its holdings in shares of Celcuity by 59.0% during the first quarter. Baker BROS. Advisors LP now owns 4,257,735 shares of the company’s stock worth $43,046,000 after buying an additional 1,579,182 shares in the last quarter. Apis Capital Advisors LLC bought a new stake in Celcuity in the 3rd quarter valued at approximately $38,334,000. UBS Group AG boosted its position in Celcuity by 910.1% during the 3rd quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after acquiring an additional 769,891 shares during the last quarter. Deerfield Management Company L.P. acquired a new position in Celcuity during the 3rd quarter worth approximately $36,236,000. Finally, Alliancebernstein L.P. grew its stake in shares of Celcuity by 2,208.6% during the 3rd quarter. Alliancebernstein L.P. now owns 652,649 shares of the company’s stock worth $32,241,000 after acquiring an additional 624,379 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.